低凝血因子 VIII 水平合并心房颤动的甲型血友病携带者血栓形成风险的管理：一例临床病例及文献综述
Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review.
作者信息
Murray Nigel P, Muñoz Lorena, Minzer Simona, Lopez Marco Antonio
机构信息
Consultant Hematologist, Dept of Medicine, Hospital de Carabineros, Simon Boliovar 2200, Nuñoa, 7770199 Santiago, Chile.
Profesor Hematology, Faculty of Medicine, University Finis Terrae, Pedro de Valdivia 1509, Providencia, 7501015 Santiago de, Chile.
出版信息
Case Rep Hematol. 2018 Sep 5;2018:2615838. doi: 10.1155/2018/2615838. eCollection 2018.
Abstract
Nonvalvular atrial fibrillation (AF) is a common age-related arrthymia and a leading cause of stroke in the elderly; with an aging hemophilia population, the number of patients developing AF is increasing. There are no controlled trials on thromboprophylaxis in this group of patients, only consensus opinion was based on small case reports. We present a female patient, carrier for hemophilia and with clinically moderately severe hemophilia who developed FA. We discuss the literature with respect to this group of patients and current recommendations for thromboprophylaxis.
摘要
非瓣膜性心房颤动（AF）是一种常见的与年龄相关的心律失常，也是老年人中风的主要原因；随着血友病患者群体的老龄化，发生AF的患者数量正在增加。对于这组患者的血栓预防尚无对照试验，仅基于小病例报告形成了共识意见。我们报告一例女性血友病携带者，临床诊断为中度严重血友病，她发生了房颤。我们讨论了关于这组患者的文献以及当前的血栓预防建议。
相似文献
1
Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review.低凝血因子 VIII 水平合并心房颤动的甲型血友病携带者血栓形成风险的管理：一例临床病例及文献综述
Case Rep Hematol. 2018 Sep 5;2018:2615838. doi: 10.1155/2018/2615838. eCollection 2018.
2
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.达比加群酯用于非瓣膜性心房颤动的卒中预防：聚焦老年人群
Consult Pharm. 2014 Mar;29(3):169-78. doi: 10.4140/TCP.n.2014.169.
4
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.肾功能障碍作为非瓣膜性心房颤动患者中风和全身性栓塞的预测因子：ROCKET AF（利伐沙班每日一次，口服，直接 Xa 因子抑制与维生素 K 拮抗剂预防中风和房颤试验）和 ATRIA（心房颤动抗凝和危险因素）研究队列中 R(2)CHADS(2)指数的验证。
Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.
5
Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.直接口服抗凝剂：用于预防非瓣膜性心房颤动患者中风的关键考量因素。
Vasc Health Risk Manag. 2015 Jun 10;11:317-32. doi: 10.2147/VHRM.S79065. eCollection 2015.
6
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.性别是否会影响非瓣膜性心房颤动患者预防中风时抗凝药物的使用？FIELD-心房颤动前瞻性全球抗凝登记研究。
Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556. Epub 2015 Feb 24.
7
Guidelines for stroke prevention in patients with atrial fibrillation.心房颤动患者卒中预防指南。
Drugs. 1999 Dec;58(6):997-1009. doi: 10.2165/00003495-199958060-00004.
8
Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age.使用心房颤动决策支持工具进行心房颤动的血栓预防：性别和年龄的影响。
J Am Geriatr Soc. 2016 May;64(5):1054-60. doi: 10.1111/jgs.14099.
9
Insights from the RCPE UK Consensus Conference on approaching the comprehensive management of atrial fibrillation.英国皇家内科医师学会房颤综合管理共识会议的见解
Expert Rev Cardiovasc Ther. 2012 Jun;10(6):697-700. doi: 10.1586/erc.12.48.
10
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).在每日口服一次利伐沙班、直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞试验（ROCKET AF）中，与华法林相比，利伐沙班在老年非瓣膜性心房颤动患者中的疗效和安全性。
Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.
引用本文的文献
1
Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.先天性血友病患者心房颤动的当前治疗方法
J Pers Med. 2022 Mar 23;12(4):519. doi: 10.3390/jpm12040519.
2
Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation.比较达比加群与Xa因子抑制剂在非瓣膜性心房颤动血友病患者中预防卒中的安全性和有效性。
J Atr Fibrillation. 2019 Dec 31;12(4):2157. doi: 10.4022/jafib.2157. eCollection 2019 Dec.
3
Challenges facing community-dwelling adults with hemophilia: Implications for community-based adult education and nursing.血友病成年社区居民面临的挑战：对社区成人教育和护理的启示。
J Int Med Res. 2020 Jan;48(1):300060519862101. doi: 10.1177/0300060519862101. Epub 2019 Jul 16.
本文引用的文献
1
Comparison of HAS-BLED and HAS-BED Versus CHADS and CHADSVASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation.心房颤动患者中HAS - BLED和HAS - BED与CHADS和CHADSVASC卒中及出血评分的比较
Am J Cardiol. 2017 Apr 1;119(7):1012-1016. doi: 10.1016/j.amjcard.2016.12.007. Epub 2017 Jan 26.
2
New concepts for anticoagulant therapy in persons with hemophilia.血友病患者抗凝治疗的新概念。
Blood. 2016 Nov 17;128(20):2471-2474. doi: 10.1182/blood-2016-07-727032. Epub 2016 Sep 26.
3
How I treat patients with inherited bleeding disorders who need anticoagulant therapy.我如何治疗需要抗凝治疗的遗传性出血性疾病患者。
Blood. 2016 Jul 14;128(2):178-84. doi: 10.1182/blood-2015-12-635094. Epub 2016 Apr 22.
4
Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).用于接受消融治疗的心房颤动患者预防卒中的口服抗凝治疗：来自首届欧洲心房颤动消融手术流程快照调查（ESS-PRAFA）的结果
Europace. 2015 Jun;17(6):986-93. doi: 10.1093/europace/euv132.
5
Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey.血友病成年患者急性冠脉综合征的表现与管理：一项国际回顾性10年调查结果
Haemophilia. 2015 Sep;21(5):589-97. doi: 10.1111/hae.12652. Epub 2015 Feb 17.
6
Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.甲型和乙型血友病患者心血管疾病治疗的共识性综述。
Cardiol Rev. 2015 Mar-Apr;23(2):53-68. doi: 10.1097/CRD.0000000000000045.
7
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.前瞻性随机评估 Watchman 左心耳封堵装置在房颤患者与长期华法林治疗中的效果：PREVAIL 试验。
J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029.
8
Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe.血友病患者的心房颤动：欧洲的一项横断面评估
Haemophilia. 2014 Sep;20(5):682-6. doi: 10.1111/hae.12445. Epub 2014 Apr 14.
9
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.使用达比加群欧洲标签的患者预后。RE-LY数据库的事后分析。
Thromb Haemost. 2014 May 5;111(5):933-42. doi: 10.1160/TH13-09-0734. Epub 2013 Dec 11.
10
Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation?CHA2DS2-VASc 是否能改善绝经后女性心房颤动患者的卒中风险分层？
Am J Med. 2013 Dec;126(12):1143.e1-8. doi: 10.1016/j.amjmed.2013.05.023. Epub 2013 Oct 17.
Zotero 插件